The short version: weekly injections still post the largest average weight loss in their pivotal trials, the Wegovy pill comes close but has strict morning food-and-water rules, and Foundayo (orforglipron) is the most convenient pill with no food or water restrictions but a smaller average loss in its main trial. None of these trials compared all the options head to head, so treat the percentages as a rough guide, not a ranking. For men who train, the practical differences are timing around meals, how dose escalation fits a training block, and protecting muscle on any of them.
The four options side by side
| Foundayo (orforglipron) | Wegovy pill (oral semaglutide) | Wegovy injection | Zepbound injection | |
|---|---|---|---|---|
| Type | Small-molecule GLP-1 agonist | Peptide (semaglutide) | Peptide (semaglutide) | Peptide (tirzepatide, GIP/GLP-1) |
| How often | Once daily | Once daily, in the morning | Once weekly | Once weekly |
| Food and water rules | None on the label | Empty stomach, a small sip of water (up to 4 oz), wait 30 minutes before food, drink or other oral meds | None tied to meals | None tied to meals |
| FDA approval | April 2026 | December 2025 | 2021 | 2023 |
| Pivotal trial result | ATTAIN-1: 11.1% at 72 weeks, highest dose, counting everyone (12.4% among those who stayed on treatment) | OASIS 4: 13.6% at 64 weeks (25 mg), counting everyone (16.6% among those who stayed on treatment) | STEP 1: about 15% at 68 weeks | SURMOUNT-1: about 21% at 72 weeks (highest dose) |
Percentages are average weight loss in each drug's own trial, with different populations and durations. They are not head-to-head comparisons.
Foundayo (orforglipron): the no-rules pill
Lilly's orforglipron was approved as Foundayo for adults with obesity, or overweight with weight-related conditions. It's taken once daily, and the label puts no restrictions on food or water timing. That's the headline feature, and it's a real one if your mornings revolve around training and a pre-lift meal.
Like the injections, Foundayo starts at a low dose and is increased in steps over several months, based on response and tolerability. Your prescriber sets the dose and the schedule.
In ATTAIN-1, the 72-week trial, average weight loss among people who stayed on treatment was 7.8%, 9.3% and 12.4% at the three trial doses of 6, 12 and 36 mg. Counting everyone randomized, whether or not they finished, the highest dose produced 11.1% versus 2.1% on placebo. The trial doses were expressed differently from the marketed tablet strengths, so don't map them one-to-one. The most common side effects were gastrointestinal and mostly mild to moderate. Lilly launched it through LillyDirect in April 2026, and Healio reported a self-pay price of $149 a month for the lowest dose at launch. Check the current price before you rely on that figure.
The Wegovy pill: semaglutide by mouth, with rules
Novo Nordisk's oral semaglutide was approved for weight management in December 2025 and launched in the US in January 2026. It comes in 1.5, 4, 9 and 25 mg tablets, with gradual escalation. Its approved uses include chronic weight management and cardiovascular risk reduction in adults with established heart disease and obesity or overweight.
The catch is absorption. Oral semaglutide is a peptide, and the label's administration rules exist to get enough of it absorbed: take it in the morning on an empty stomach with no more than 4 oz of water, then wait at least 30 minutes before eating, drinking anything else or taking other oral medications. If your routine is wake up, coffee, pre-workout meal, train, that rule changes your morning.
In OASIS 4, the 64-week trial, average weight loss on the 25 mg pill was 13.6% versus 2.2% on placebo, counting everyone randomized whether or not they kept taking it. Among those who stayed on treatment it was 16.6%.
Weekly injections: still the benchmark
Injectable semaglutide (Wegovy) and tirzepatide (Zepbound) are taken once a week, with no meal timing to manage. In their pivotal trials, average weight loss was about 15% at 68 weeks on Wegovy (STEP 1) and about 21% at 72 weeks on the highest Zepbound dose (SURMOUNT-1). Both drugs have the longest track record of the four options here. Our profiles of semaglutide and tirzepatide go further into how they work.
The trade-off is the needle and the weekly cadence. Some men prefer one shot a week to a daily pill. Others want nothing to do with injections. Neither choice is wrong.
What matters for men who train
Meal timing and training
Foundayo's lack of food rules makes it the easiest to fit around early training. With the Wegovy pill, the 30-minute wait applies to food, drinks and other oral medications, so plan your morning around it with your prescriber. With weekly shots, you'll mostly be planning around which days GI side effects show up after a dose.
Dose escalation and training blocks
All four drugs escalate over weeks to months, and GI side effects tend to cluster around increases. If you're planning a heavy training block or a meet, talk to your prescriber about timing. Don't adjust doses on your own.
Lean mass
Lean mass made up about 38 to 39% of weight lost in the STEP 1 body-composition substudy and about 25% in SURMOUNT-1, as summarized by Barbell Medicine. Measurement caveats apply, but the lesson is the same for every format: resistance training and adequate protein aren't optional extras. See the muscle-loss problem.
Compounded versions
There are no approved generic versions of these drugs. FDA's current position is that compounded GLP-1s should be used only when an FDA-approved drug can't meet a patient's medical needs, and it has flagged salt-form semaglutide as having no known lawful basis for compounding. If a telehealth program offers you a "compounded" alternative to a brand pill, ask why and what's in it.
Cost and access
Brand pricing has changed fast in 2025–2026, with manufacturer self-pay channels and government-negotiated pricing. Our TrumpRx brand GLP-1 pricing post covers that shift. Verify any price on the manufacturer's site the day you buy. Before you sign up for a telehealth program, run through our GLP-1 telehealth questions.
How to decide, with your prescriber
- Needle tolerance: if injections are a non-starter, it's a pill question.
- Morning routine: if you train early and eat right away, Foundayo's lack of food rules is easier than the Wegovy pill's.
- Size of the goal: the injections, especially tirzepatide, posted the largest average trial losses.
- Heart disease: semaglutide products carry a cardiovascular risk-reduction indication for eligible adults. Ask whether that applies to you.
- Cost and coverage: compare your insurance coverage with the manufacturers' self-pay channels.
Telehealth programs we link to
Dosing for GLP-1 medications is set by the prescribing clinician. See our medical disclaimer.
Severe or persistent abdominal pain, repeated vomiting, signs of dehydration, or a lump or swelling in the neck need prompt medical attention, whatever format you're on.
Sources
- Healio, FDA approves orforglipron, an oral GLP-1 for adults with obesity (April 1, 2026): indication, ATTAIN-1 results, launch and self-pay price.
- Eli Lilly press release via BioSpace, FDA approves Lilly's Foundayo (orforglipron) (April 2026): ATTAIN-1 efficacy-estimand (12.4% vs 0.9%) and treatment-regimen-estimand (11.1% vs 2.1%) results.
- Wharton et al., Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity, N Engl J Med 2025 (OASIS 4): 13.6% vs 2.2% regardless of adherence; 16.6% vs 2.7% if all participants adhered, per Novo Nordisk's September 2025 release.
- NowPatient, Everything you need to know about FDA-approved Wegovy pills: approval date, strengths, administration rules and OASIS 4 result, citing the FDA label (December 2025) and Wharton et al., N Engl J Med 2025;393:1077–1087.
- Barbell Medicine, GLP-1s and muscle loss: STEP 1 and SURMOUNT-1 weight-loss and lean-mass summaries, citing Wilding 2021 and Jastreboff 2022.
- FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026).
Frequently Asked
Yes. Foundayo (orforglipron), approved in April 2026, is taken once daily, and its label puts no restrictions on food or water. The Wegovy pill must be taken on an empty stomach with up to 4 ounces of water, followed by a 30-minute wait before food, drink or other oral medicines.
In their own pivotal trials, counting everyone randomized, the Wegovy pill (25 mg) produced 13.6 percent average weight loss at 64 weeks and Foundayo 11.1 percent at 72 weeks at its highest dose, compared with about 15 percent for weekly Wegovy injections and about 21 percent for the highest Zepbound dose. These were separate trials, not head-to-head comparisons.
Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist from Eli Lilly, sold as Foundayo. It is FDA-approved for adults with obesity or with overweight and weight-related conditions.
Lean-mass loss has been documented with GLP-1 drugs generally, and there is no reason to assume pills are different. Resistance training and adequate protein are the main tools for protecting muscle on any format.
There are no approved generic versions of these drugs, and FDA says compounded GLP-1s should be used only when an approved drug cannot meet a patient's medical needs. Ask any program offering a compounded alternative exactly what is in it and which pharmacy makes it.